Boldfit is a direct-to-consumer brand that specializes in fitness products, offering a range of gym equipment and nutritional supplements to support your fitness journey. Its fitness product categories include resistance bands, yoga mats, bottles and shakers, and home gym accessories. Bold Fit also provides proteins, recovery, and intra supplements, as well as daily essentials, omega 3, detox, bone, and joint health nutrition supplements.
Oshi Health
Series C in 2024
Oshi Health is a virtual-first gastroenterology clinic focused on diagnosing, treating, and remotely monitoring digestive conditions. The company employs an integrated care team comprising gastroenterologists, GI-specialized nurse practitioners, registered dietitians, behavioral psychologists, and health coaches. This multidisciplinary approach allows patients to identify the root causes of their symptoms and develop personalized care plans that incorporate medication, dietary changes, and gut-brain behavioral therapy. Oshi Health aims to enhance access to digestive health care, improve patient experiences, and achieve better clinical outcomes, ultimately helping patients gain lasting control over their symptoms and improve their quality of life.
Oshi Health
Series B in 2023
Oshi Health is a virtual-first gastroenterology clinic focused on diagnosing, treating, and remotely monitoring digestive conditions. The company employs an integrated care team comprising gastroenterologists, GI-specialized nurse practitioners, registered dietitians, behavioral psychologists, and health coaches. This multidisciplinary approach allows patients to identify the root causes of their symptoms and develop personalized care plans that incorporate medication, dietary changes, and gut-brain behavioral therapy. Oshi Health aims to enhance access to digestive health care, improve patient experiences, and achieve better clinical outcomes, ultimately helping patients gain lasting control over their symptoms and improve their quality of life.
Oshi Health
Series A in 2021
Oshi Health is a virtual-first gastroenterology clinic focused on diagnosing, treating, and remotely monitoring digestive conditions. The company employs an integrated care team comprising gastroenterologists, GI-specialized nurse practitioners, registered dietitians, behavioral psychologists, and health coaches. This multidisciplinary approach allows patients to identify the root causes of their symptoms and develop personalized care plans that incorporate medication, dietary changes, and gut-brain behavioral therapy. Oshi Health aims to enhance access to digestive health care, improve patient experiences, and achieve better clinical outcomes, ultimately helping patients gain lasting control over their symptoms and improve their quality of life.
Spero Foods
Series A in 2021
Spero Foods, Inc. is a company that specializes in producing and selling alternative dairy products, focusing primarily on cream cheese. Founded in 2016 and headquartered in Oakland, California, Spero employs innovative food science and process engineering to create mainstream plant-based dairy alternatives. The company aims to provide healthy food options for all individuals, positioning itself as a disruptor in the traditional dairy market. Spero Foods' products are available through various channels, including wholesalers, retail stores, and online platforms across the United States. The company has gained recognition for its innovative approach and has received awards from notable organizations such as Fast Company, NEXTY, and The Food Network. Its products can be found in over 3,500 authorized locations, including major retailers like Kroger, Whole Foods, Publix, and Sprouts.
Allena Pharmaceuticals
Post in 2017
Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company based in Newton, Massachusetts, focused on the development and commercialization of innovative oral enzyme therapeutics for rare and severe metabolic and kidney disorders. Founded in 2011, the company’s lead product candidate, reloxaliase, is currently undergoing a pivotal Phase 3 clinical program aimed at treating enteric hyperoxaluria, a condition characterized by elevated urinary oxalate levels that can lead to kidney stones and chronic kidney disease. Additionally, Allena is developing ALLN-346, a novel enzyme intended to address hyperuricemia in patients with moderate to severe chronic kidney diseases. By targeting metabolic disorders associated with the accumulation of harmful metabolites, Allena Pharmaceuticals aims to provide effective treatments for patients facing serious health challenges.
Allena Pharmaceuticals
Series B in 2014
Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company based in Newton, Massachusetts, focused on the development and commercialization of innovative oral enzyme therapeutics for rare and severe metabolic and kidney disorders. Founded in 2011, the company’s lead product candidate, reloxaliase, is currently undergoing a pivotal Phase 3 clinical program aimed at treating enteric hyperoxaluria, a condition characterized by elevated urinary oxalate levels that can lead to kidney stones and chronic kidney disease. Additionally, Allena is developing ALLN-346, a novel enzyme intended to address hyperuricemia in patients with moderate to severe chronic kidney diseases. By targeting metabolic disorders associated with the accumulation of harmful metabolites, Allena Pharmaceuticals aims to provide effective treatments for patients facing serious health challenges.
Allena Pharmaceuticals
Series A in 2011
Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company based in Newton, Massachusetts, focused on the development and commercialization of innovative oral enzyme therapeutics for rare and severe metabolic and kidney disorders. Founded in 2011, the company’s lead product candidate, reloxaliase, is currently undergoing a pivotal Phase 3 clinical program aimed at treating enteric hyperoxaluria, a condition characterized by elevated urinary oxalate levels that can lead to kidney stones and chronic kidney disease. Additionally, Allena is developing ALLN-346, a novel enzyme intended to address hyperuricemia in patients with moderate to severe chronic kidney diseases. By targeting metabolic disorders associated with the accumulation of harmful metabolites, Allena Pharmaceuticals aims to provide effective treatments for patients facing serious health challenges.
Mothernature.com
Series B in 1999
Mothernature.com is an online retail store based in Doargo, Florida, specializing in vitamins, minerals, supplements, and other products related to natural and healthy living. The company aims to be a leading destination for consumers seeking earth-friendly products by combining an extensive range of offerings with informative content. In addition to its product selection, Mothernature.com provides free health information contributed by a panel of medical experts, enhancing its role as a resource for health-conscious individuals. Through this innovative approach, the company seeks to establish itself as a trusted source for natural wellness solutions.
Mothernature.com
Series A in 1998
Mothernature.com is an online retail store based in Doargo, Florida, specializing in vitamins, minerals, supplements, and other products related to natural and healthy living. The company aims to be a leading destination for consumers seeking earth-friendly products by combining an extensive range of offerings with informative content. In addition to its product selection, Mothernature.com provides free health information contributed by a panel of medical experts, enhancing its role as a resource for health-conscious individuals. Through this innovative approach, the company seeks to establish itself as a trusted source for natural wellness solutions.